Congenica is a UK company founded on pioneering research from the Wellcome Trust Sanger Institute, NHS clinicians and regional genetic testing laboratories.

Telephone: +44 (0)1223 499 965
Address: BioData Innovation Centre, Wellcome Genome Campus, Hinxton
Postcode: CB10 1DR
Country: United Kingdom
Membership type:Corporate 51+ (£1,000+VAT pa)

We’ve translated this research into the gold standard clinical genomic analytics platform, Sapientia®, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide actionable interpretation of genetic disease for patients.

Our platform is used by clinicians and researchers across the world for clinical diagnosis, prognosis, and research. Many of the UK Regional Genetics Centres are using Sapientia as a decision support platform, in addition to clinical laboratories in other countries.  It is also being leveraged by several prolific research projects, as well as by UCB Pharma.  Sapientia has many other applications in personalised medicine, such as creating disease registries, identifying patient populations for clinical studies, and discovering novel drug targets and biomarkers.

Congenica achieves global ISO 13485:2016 in vitro diagnostic device quality management system

Congenica, a global provider of clinical genomics interpretation software, announced today that it has received certification in ISO 13485:2016, a quality management system for medical devices that supports comprehensive policies and processes across the entire business.

28 February 2018Read in full

Partnership aims to deliver more accurate diagnoses for genetic epilepsy

New software to deliver faster and more accurate diagnoses in genetic epilepsies is the ambition of a ground-breaking partnership between Congenica, a global provider of clinical genomics interpretation software, and FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, supported by Science Foundation Ireland.

12 February 2018Read in full

Congenica signs strategic digital health contracts during official UK-China Trade Mission

Today Congenica, the global provider of clinical genomics interpretation software, signed a series of significant memorandums of understanding (MOUs) with leading Chinese companies and healthcare providers at a UK-Chinese Future of Medicine trade event in Beijing, China. The meeting was held in conjunction with the State visit of Prime Minister May.

1 February 2018Read in full

Congenica appoints new CEO to drive global expansion of clinical genomics business

Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer, David Atkins, PhD. Based at the Company’s headquarters in Cambridge, Dr Atkins also joins Congenica’s Board of Directors.

25 January 2018Read in full

Congenica’s Sapientia™ selected for Portugal’s In2Genome genetic disease diagnosis project

Congenica, a global provider of clinical genomics interpretation software, today announced a new customer partnership with the Coimbra Paediatric Hospital (CPH), a leading paediatric hospital in Portugal and part of the Coimbra Hospital and University Centre (CHUC).

6 September 2017Read in full

China’s '100K Wellness Pioneer Project' uses UniteGen and Sapientia™ integrated platform

Congenica’s Sapientia™ clinical genome analysis software platform will be used by China-based UniteGen to carry out whole genome sequencing (WGS) processing and analysis as part of China’s “100K Wellness Pioneer Project”, hosted by Beijing 4P Health Research Institute.

22 June 2017Read in full

Congenica completes Series B financing with investments from BGI, Healthlink & Future Planet

Congenica, a world leader in clinical genomics software for inherited diseases, today announced completion of its recently announced Series B funding round with additional investments from new strategically important investors BGI Genomics (BGI), a recognized global leader in genomics, Healthlink Capital (Healthlink), another well-established China-based life- science investor and Future Planet Capital, a global innovation fund.

27 April 2017Read in full

New partnership to speed analysis from ‘DNA to diagnosis’ for inherited diseases

Congenica and Edico Genome have announced the companies have partnered to offer their complementary platform technologies as an all-in-one, genome data analysis solution that accelerates clinical labs’ and hospitals’ progression from DNA sequencing to diagnosis for inherited diseases which otherwise takes months or years.

21 April 2017Read in full

Congenica raises £8M ($10M) in Series B financing round to drive international expansion

Congenica, a leading provider of clinical genome analysis technology, announced today that it has raised £8m ($10m) in its Series B financing round. Existing investors, Cambridge Innovation Capital plc (CIC) and Amadeus Capital Partners participated alongside new investor, Parkwalk Advisors.

27 February 2017Read in full

Nick Lench, COO Congenica

Whole genome analysis leads to faster diagnosis and cost benefits

“Rare Disease Diagnosis – Shortening Odysseys, Improving Outcomes” is the title of a presentation by Congenica at the Precision Medicine World Conference (PMWC) 2017 on Monday (January 23).

20 January 2017Read in full

  1. 1
  2. 2